Eli Lilly reported Thursday that in a late-stage trial, its next-generation obesity drug led to levels of weight loss approaching those seen with bariatric surgery. However, the study also revealed high rates of adverse events and discontinuations, raising concerns about the treatment's practicality.
In the Phase 3 study, which enrolled obese and overweight individuals without diabetes, participants who took the highest dose and adhered to the regimen for 80 weeks lost on average 28.3% of their body weight. Despite this impressive result, 11% of patients in the highest-dose group discontinued due to adverse events, and when analyzing all participants, including those who dropped out, the overall efficacy was only 25%.
In pivotal trials of other obesity drugs already on the market—such as Novo Nordisk's Wegovy and Lilly’s Zepbound—the discontinuation rates due to side effects were up to 7%. These figures suggest that while retatrutide showed promising weight loss potential, its high rate of adverse events could make it less appealing for widespread use.
The study highlights the ongoing challenges in developing effective treatments for obesity. While near-bariatric surgery levels of weight loss are a significant achievement, the side effects and discontinuation rates raise questions about how widely this drug might be adopted by patients seeking to manage their weight. Further research will be needed to address these issues and determine whether retatrutide can become a viable option in the fight against obesity. Continue to for more details on the study's findings and implications.
